XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)
 12 Months Ended
May 13, 2024
USD ($)
Mar. 31, 2024
USD ($)
Compounds
shares
Mar. 31, 2023
USD ($)
shares
May 29, 2024
USD ($)
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Cash and cash equivalents   $ 2,901,000 $ 15,301,000  
Restricted cash   143,000 143,000  
Accumulated deficit   (339,669,000) (324,998,000)  
Cash flow from operations   $ 14,653,000 $ 12,408,000  
Issuance of common stock | shares   10,077,726 8,716,906  
Proceeds from sale of common stock shares   $ 1,437,000 $ 0  
Restricted cash   $ 100,000 100,000  
Inventory finished goods     0  
Estimated useful life of the fixed assets   The estimated useful lives of the fixed assets range between one and seven years.    
Impairment of long-lived assets   $ 0 0  
Acquired in-process research and development accrued expenses   0 2,000,000  
Dilutive effect   $ 0 $ 0  
Common stock equivalents excluded from computing diluted net loss per share | shares   800,000 1,600,000  
Subsequent Event [Member]        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Cash and cash equivalents       $ 7,000,000
Maximum [Member]        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Maturity of highly liquid investment   3 months    
Useful life of fixed assets, range   7 years    
Minimum [Member]        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Useful life of fixed assets, range   1 year    
Mosaic Cell Sciences [Member]        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Inventory finished goods   $ 0.3    
At-The-Market Facility [Member]        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Issuance of common stock | shares   1,172,342    
Public Offering [Member] | Subsequent Event [Member]        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Net proceeds from issuance of offerings $ 4,700,000      
Metacrine's FXR Program [Member]        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Number of clinically tested compounds | Compounds   2    
Number of discovery or preclinical compounds | Compounds   2,000    
Metacrine, Inc. [Member] | Metacrine's FXR Program [Member]        
Description Of Business And Summary Of Significant Accounting Policies [Line Items]        
Asset Acquisition, Price of Acquisition, Expected     $ 4,000,000  
Upfront payment paid     $ 2,000,000  
Acquired in-process research and development accrued expenses   $ 2,000,000